A Single Center, Randomized, Open-Label, Sequential, Single Dose, 3-Period Crossover Study to Evaluate the Bioavailability and Food Effect of a Gelatin Formulation and Immediate Release Tablet Formulation of Afuresertib, an AKT Inhibitor, in Normal Healthy Volunteers
Phase of Trial: Phase I
Latest Information Update: 15 Nov 2017
Price : $35 *
At a glance
- Drugs Afuresertib (Primary)
- Indications Chronic lymphocytic leukaemia; Haematological malignancies; Histiocytosis; Multiple myeloma; Ovarian cancer; Solid tumours
- Focus Pharmacokinetics
- Sponsors GlaxoSmithKline
- 18 Apr 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 28 Mar 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
- 13 Feb 2014 Status changed from not yet recruiting to recruiting according ClinicalTrials.gov record.